In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism

被引:0
|
作者
David Erritzoe
Andri Tziortzi
David Bargiela
Alessandro Colasanti
Graham E Searle
Roger N Gunn
John D Beaver
Adam Waldman
David J Nutt
Massimo Bani
Emilio Merlo-Pich
Eugenii A Rabiner
Anne Lingford-Hughes
机构
[1] Centre for Neuropsychopharmacology,Division of Brain Sciences
[2] Faculty of Medicine,Department of Clinical Neurology
[3] Imperial College London,Division of Brain Sciences, Department of Medicine
[4] Clinical Imaging Centre,Department of Imaging
[5] GlaxoSmithKline,undefined
[6] FMRIB Centre,undefined
[7] University of Oxford,undefined
[8] Imperial College London,undefined
[9] Charing Cross Hospital,undefined
[10] CEDD for Neurosciences,undefined
[11] GlaxoSmithKline,undefined
来源
Neuropsychopharmacology | 2014年 / 39卷
关键词
PET; dopamine; D3; alcohol addiction; PHNO;
D O I
暂无
中图分类号
学科分类号
摘要
Animal studies support the role of the dopamine D3 receptor (DRD3) in alcohol reinforcement or liking. Sustained voluntary alcohol drinking in rats has been associated with an upregulation of striatal DRD3 gene expression and selective blockade of DRD3 reduces ethanol preference, consumption, and cue-induced reinstatement. In vivo measurement of DRD3 in the living human brain has not been possible until recently owing to a lack of suitable tools. In this study, DRD3 status was assessed for the first time in human alcohol addiction. Brain DRD3 availability was compared between 16 male abstinent alcohol-dependent patients and 13 healthy non-dependent age-matched males using the DRD3-preferring agonist positron emission tomography (PET) radioligand [11C]PHNO with and without blockade with a selective DRD3 antagonist (GSK598809 60 mg p.o.). In striatal regions of interest, where the [11C]PHNO PET signal represents primarily DRD2 binding, no differences were seen in [11C]PHNO binding between the groups at baseline. However, baseline [11C]PHNO binding was higher in alcohol-dependent patients in hypothalamus (VT: 16.5±4 vs 13.7±2.9, p=0.040), a region in which the [11C]PHNO signal almost entirely reflects DRD3 availability. The reductions in regional receptor binding (VT) following a single oral dose of GSK598809 (60 mg) were consistent with those observed in previous studies across all regions. There were no differences in regional changes in VT following DRD3 blockade between the two groups, indicating that the regional fractions of DRD3 are similar in the two groups, and the increased [11C]PHNO binding in the hypothalamus in alcohol-dependent patients is explained by elevated DRD3 in this group. Although we found no difference between alcohol-dependent patients and controls in striatal DRD3 levels, increased DRD3 binding in the hypothalamus of alcohol-dependent patients was observed. This may be relevant to the development of future therapeutic strategies to treat alcohol abuse.
引用
收藏
页码:1703 / 1712
页数:9
相关论文
共 50 条
  • [1] In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism
    Erritzoe, David
    Tziortzi, Andri
    Bargiela, David
    Colasanti, Alessandro
    Searle, Graham E.
    Gunn, Roger N.
    Beaver, John D.
    Waldmans, Adam
    Nutt, David J.
    Bani, Massimo
    Merlo-Pich, Emilio
    Rabiner, Eugenii A.
    Lingford-Hughes, Anne
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 (07) : 1703 - 1712
  • [2] In vivo imaging of dopamine D3 receptors in alcoholism using [11C]PHNO-PET, and a selective D3 receptor antagonist
    Erritzoe, D.
    Tziortzi, A.
    Bargiela, D.
    Searle, G.
    Gunn, R. N.
    Beaver, J. D.
    Waldman, A.
    Nutt, D. J.
    Bani, M.
    Merlo-Pich, E.
    Rabiner, E. A.
    Lingford-Hughes, A.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2012, 32 : S77 - S78
  • [3] In Vivo Imaging of Dopamine D3 Receptors in Alcoholism Using Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist
    Erritzoe, David
    Tziortzi, Andri
    Bargiela, David
    Searle, Graham
    Gunn, Roger N.
    Beaver, John D.
    Waldman, Adam
    Nutt, David
    Bani, Massimo
    Merlo-Pich, Emilio
    Rabiner, Eugenii A.
    Lingford-Hughes, Anne
    BIOLOGICAL PSYCHIATRY, 2011, 69 (09) : 271S - 271S
  • [4] Selectivity of probes for PET imaging of dopamine D3 receptors
    Doot, Robert K.
    Dubroff, Jacob G.
    Labban, Kyle J.
    Mach, Robert H.
    NEUROSCIENCE LETTERS, 2019, 691 : 18 - 25
  • [5] The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors
    Wicke, K
    Garcia-Ladona, J
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 424 (02) : 85 - 90
  • [6] Analysis of mutant D3 dopamine receptors in vitro, and D3 receptor neuron development in vivo.
    Heitz, F
    Plagge, A
    McAllister, G
    Ragan, I
    Allen, N
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 : 403 - 403
  • [7] Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo
    Beaulieu, Jean-Martin
    Tirotta, Emanuele
    Sotnikova, Tatyana D.
    Masri, Bernard
    Salahpour, Ali
    Gainetdinov, Raul R.
    Borrelli, Emiliana
    Caron, Marc G.
    JOURNAL OF NEUROSCIENCE, 2007, 27 (04): : 881 - 885
  • [8] Motivating interest in D3 dopamine receptors
    Tritsch, Nicolas X.
    NATURE NEUROSCIENCE, 2025, 28 (01) : 6 - 7
  • [9] A new look at dopamine D3 receptors
    Accili, D
    Fuchs, S
    MOLECULAR PSYCHIATRY, 1996, 1 (02) : 93 - 94
  • [10] Affinity of dopamine for the D3 and D2 high receptors in the human brain in vivo
    Rabiner, Eugenii
    Shotbolt, Paul
    Tziortzi, Andri
    Searle, Graham
    Laruelle, Marc
    Gunn, Roger
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52